WOCKHARDT | ZYDUS LIFESCIENCES | WOCKHARDT/ ZYDUS LIFESCIENCES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -12.0 | 19.1 | - | View Chart |
P/BV | x | 0.9 | 2.3 | 38.3% | View Chart |
Dividend Yield | % | 0.0 | 0.7 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
WOCKHARDT Mar-22 |
ZYDUS LIFESCIENCES Mar-22 |
WOCKHARDT/ ZYDUS LIFESCIENCES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 805 | 674 | 119.4% | |
Low | Rs | 253 | 331 | 76.5% | |
Sales per share (Unadj.) | Rs | 224.3 | 149.1 | 150.4% | |
Earnings per share (Unadj.) | Rs | -19.4 | 22.7 | -85.2% | |
Cash flow per share (Unadj.) | Rs | -2.2 | 29.7 | -7.5% | |
Dividends per share (Unadj.) | Rs | 0 | 2.50 | 0.0% | |
Avg Dividend yield | % | 0 | 0.5 | 0.0% | |
Book value per share (Unadj.) | Rs | 266.0 | 166.1 | 160.2% | |
Shares outstanding (eoy) | m | 144.03 | 1,023.74 | 14.1% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.4 | 3.4 | 70.0% | |
Avg P/E ratio | x | -27.3 | 22.1 | -123.5% | |
P/CF ratio (eoy) | x | -238.0 | 16.9 | -1,406.7% | |
Price / Book Value ratio | x | 2.0 | 3.0 | 65.7% | |
Dividend payout | % | 0 | 11.0 | 0.0% | |
Avg Mkt Cap | Rs m | 76,168 | 514,277 | 14.8% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 7,490 | 21,777 | 34.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 32,300 | 152,652 | 21.2% | |
Other income | Rs m | 200 | 2,354 | 8.5% | |
Total revenues | Rs m | 32,500 | 155,006 | 21.0% | |
Gross profit | Rs m | 1,150 | 34,427 | 3.3% | |
Depreciation | Rs m | 2,470 | 7,130 | 34.6% | |
Interest | Rs m | 2,990 | 1,270 | 235.4% | |
Profit before tax | Rs m | -4,110 | 28,381 | -14.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -1,320 | 5,117 | -25.8% | |
Profit after tax | Rs m | -2,790 | 23,264 | -12.0% | |
Gross profit margin | % | 3.6 | 22.6 | 15.8% | |
Effective tax rate | % | 32.1 | 18.0 | 178.1% | |
Net profit margin | % | -8.6 | 15.2 | -56.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 25,890 | 122,614 | 21.1% | |
Current liabilities | Rs m | 32,070 | 78,394 | 40.9% | |
Net working cap to sales | % | -19.1 | 29.0 | -66.0% | |
Current ratio | x | 0.8 | 1.6 | 51.6% | |
Inventory Days | Days | 31 | 93 | 33.8% | |
Debtors Days | Days | 10 | 80 | 13.0% | |
Net fixed assets | Rs m | 50,810 | 144,382 | 35.2% | |
Share capital | Rs m | 720 | 1,024 | 70.3% | |
"Free" reserves | Rs m | 37,590 | 168,972 | 22.2% | |
Net worth | Rs m | 38,310 | 169,996 | 22.5% | |
Long term debt | Rs m | 3,550 | 3,621 | 98.0% | |
Total assets | Rs m | 76,700 | 266,996 | 28.7% | |
Interest coverage | x | -0.4 | 23.3 | -1.6% | |
Debt to equity ratio | x | 0.1 | 0 | 435.0% | |
Sales to assets ratio | x | 0.4 | 0.6 | 73.7% | |
Return on assets | % | 0.3 | 9.2 | 2.8% | |
Return on equity | % | -7.3 | 13.7 | -53.2% | |
Return on capital | % | -2.7 | 17.1 | -15.7% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 1.9 | 14.3 | 13.5% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 624 | 21,869 | 2.9% | |
Fx inflow | Rs m | 2,263 | 63,065 | 3.6% | |
Fx outflow | Rs m | 624 | 21,869 | 2.9% | |
Net fx | Rs m | 1,638 | 41,196 | 4.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,130 | 21,041 | 19.6% | |
From Investments | Rs m | -2,010 | 11,544 | -17.4% | |
From Financial Activity | Rs m | -710 | -8,683 | 8.2% | |
Net Cashflow | Rs m | 1,380 | 23,729 | 5.8% |
Indian Promoters | % | 65.8 | 74.9 | 87.8% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 2.9 | 14.9 | 19.6% | |
FIIs | % | 2.8 | 2.9 | 98.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 34.3 | 25.1 | 136.3% | |
Shareholders | 180,170 | 455,624 | 39.5% | ||
Pledged promoter(s) holding | % | 47.8 | 0.0 | - |
Compare WOCKHARDT With: SUN PHARMA DR. REDDYS LAB LUPIN CIPLA AUROBINDO PHARMA
Indian share markets rose today tracking the rally in US stocks after softer-than-expected US inflation data stoked speculation the Federal Reserve could pivot to a shallower pace of interest-rate hikes.